Carboplatin (paraplatin)
Most commonly used for the treatment of ovarian and lung cancer, Bristol Myers Squibb’s carboplatin has also been used to treat sufferers of pleural malignant mesothelioma, usually in tandem with the drug gemcitabine.
Classified as a DNA alkylating agent, this drug was first used in the late 1980s. It carries far fewer side effects than its parent compound, cisplatin. According to experts, this is due to the added stability of carboplatin in the bloodstream, which prevents proteins from binding to it, allowing it to remain in the body for a longer period of time. The flipside is that it takes larger doses in order for carboplatin to be as effective as cisplatin.
Treatment with Carboplatin
Mesothelioma patients that are treated with carboplatin or a combination of carboplatin and another chemo drug should be abreast of all the specifics of the drug, including how it is administered and other specifics.
- Carboplatin is a clear liquid that may be given intravenously.
- The drug can also be administered through a central line near the collarbone or in the crook of the arm.
Possible Side Effects of Carboplatin
- The most serious side effect of this drug is the reduction in production of white blood cells and platelets, causing an increased chance of infection and difficulty clotting. Carboplatin users should avoid contact with anyone who is ill.
- Anemia
- Nausea and/or vomiting
- Loss of appetite
- Tiredness/weakness
- Diarrhea
- Tinnitus (ringing in the ear) – most commonly associated with high doses
- Sore mouth and changes in taste
- Hair loss – most commonly associated with high doses
- Numbness or tingling in extremities